DE1038049B - Process for the preparation of therapeutically valuable 4-substituted 1, 2-diaryl-3, 5-dioxo-pyrazolidines and their salts - Google Patents
Process for the preparation of therapeutically valuable 4-substituted 1, 2-diaryl-3, 5-dioxo-pyrazolidines and their saltsInfo
- Publication number
- DE1038049B DE1038049B DEG17950A DEG0017950A DE1038049B DE 1038049 B DE1038049 B DE 1038049B DE G17950 A DEG17950 A DE G17950A DE G0017950 A DEG0017950 A DE G0017950A DE 1038049 B DE1038049 B DE 1038049B
- Authority
- DE
- Germany
- Prior art keywords
- general formula
- substituted
- meaning given
- radicals
- hydrazobenzene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 9
- 150000003839 salts Chemical class 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims description 3
- -1 alkali metal salt Chemical class 0.000 claims description 18
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 9
- 239000004215 Carbon black (E152) Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 229930195733 hydrocarbon Natural products 0.000 claims description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 238000009833 condensation Methods 0.000 claims description 3
- 230000005494 condensation Effects 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 150000007529 inorganic bases Chemical class 0.000 claims description 3
- 150000007530 organic bases Chemical class 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000007868 Raney catalyst Substances 0.000 claims description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims description 2
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 150000002690 malonic acid derivatives Chemical class 0.000 claims description 2
- PKQIDSVLSKFZQC-UHFFFAOYSA-N 3-oxobutanal Chemical compound CC(=O)CC=O PKQIDSVLSKFZQC-UHFFFAOYSA-N 0.000 claims 2
- 229910052783 alkali metal Inorganic materials 0.000 claims 2
- 150000002084 enol ethers Chemical class 0.000 claims 2
- HTARNSZGZUTMQN-UHFFFAOYSA-N 1,1,3,3-tetramethoxybutane Chemical compound COC(OC)CC(C)(OC)OC HTARNSZGZUTMQN-UHFFFAOYSA-N 0.000 claims 1
- DENWFXSPYVEERQ-UHFFFAOYSA-N CC(=O)CC=O.CC(=O)CC=O Chemical compound CC(=O)CC=O.CC(=O)CC=O DENWFXSPYVEERQ-UHFFFAOYSA-N 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 claims 1
- 229910003446 platinum oxide Inorganic materials 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- LGYTZKPVOAIUKX-UHFFFAOYSA-N kebuzone Chemical compound O=C1C(CCC(=O)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 LGYTZKPVOAIUKX-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 2
- 150000003218 pyrazolidines Chemical class 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 240000005265 Lupinus mutabilis Species 0.000 description 1
- 235000008755 Lupinus mutabilis Nutrition 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 235000019095 Sechium edule Nutrition 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- ZPTUSGWCRVFLQP-UHFFFAOYSA-N diethyl 2-[2-(2-methyl-1,3-dioxolan-2-yl)ethyl]propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)CCC1(C)OCCO1 ZPTUSGWCRVFLQP-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
DEUTSCHESGERMAN
Die Erfindung betrifft ein Verfahren zur Herstellung von 4-substituierten l^-Diaryl-SjS-dioxo-pyrazolidinen, welche sich als Arzneimittel, insbesondere zur Behandlung der Gicht, eignen.The invention relates to a process for the preparation of 4-substituted l ^ -Diaryl-SjS-dioxo-pyrazolidines, which are suitable as medicaments, especially for the treatment of gout.
Das l,2-DiphenyI-4-n-butyl-3,5-dioxo-pyrazolidin bat als Arzneimittel zur Behandlung rheumatischer Erkrankungen große Bedeutung erlangt. Es wurde nun gefunden, daß analoge Verbindungen mit dem y-Oxo-butylrest an Stelle des Butylrests, entsprechend der allgemeinen FormelThe 1,2-diphenyl-4-n-butyl-3,5-dioxo-pyrazolidine was asked as a drug for the treatment of rheumatic diseases gained great importance. It has now been found that analogous compounds with the y-oxo-butyl radical Place of the butyl residue, according to the general formula
, CO-N-Ar1 , CO-N-Ar 1
CH3-CO-CH2-CH2-CH ! ICH 3 -CO-CH 2 -CH 2 -CH! I.
\ I\ I
CO-N-Ar2 CO-N-Ar 2
und ihre Ketale der allgemeinen Formeland their ketals of the general formula
CO-N-Ar1 CO-N-Ar 1
-— C — CHo—CHo—CH- C - CHo - CHo - CH
IIII
Verfahren
zur Herstellung von therapeutischprocedure
for the manufacture of therapeutic
wertvollen 4-substituiertenvaluable 4-substituted
l,2-Diaryl-3,5-dioxo-pyrazolidinen1,2-diaryl-3,5-dioxo-pyrazolidines
sowie deren Salzenand their salts
XCO — N — Ar, X CO - N - Ar,
Anmelder:Applicant:
J. R. Geigy A.-G., Basel (Schweiz)J. R. Geigy A.-G., Basel (Switzerland)
Vertreter: Dr. F. Zumstein, Patentanwalt,
München 2, Bräuhausstr. 4Representative: Dr. F. Zumstein, patent attorney,
Munich 2, Bräuhausstr. 4th
Beanspruchte Priorität:
Schweiz vom 10. September 1954Claimed priority:
Switzerland from September 10, 1954
Dr. Rolf Denss und Dr. Franz Häfliger, Basel (Schweiz), sind als Erfinder genannt wordenDr. Rolf Denss and Dr. Franz Häfliger, Basel (Switzerland), have been named as inventors
worin Ar1 und Ar3 Phenylreste, welche an gleicher oder as verschiedener Stelle durch Halogen, Alkyl-, Alkoxy- oder Alkylmercaptogruppen substituiert sein können, und R1 und R2 Kohlenwasserstoffreste, welche auch unter sich zu einem zweiwertigen Kohlenwasserstoffrest verbunden sein können, bedeuten, ebenfalls interessante pharmakologische Eigenschaften bei geringer Toxizität aufweisen. Sie eignen sich besonders zur Behandlung der Gicht.where Ar 1 and Ar 3 are phenyl radicals which can be substituted at the same or different positions by halogen, alkyl, alkoxy or alkyl mercapto groups, and R 1 and R 2 are hydrocarbon radicals which can also be linked to form a divalent hydrocarbon radical , also have interesting pharmacological properties with low toxicity. They are particularly suitable for treating gout.
So zeigen die Verbindungen gemäß Formeln I und II am Menschen eine wesentlich stärkere uricosurische Wirkung, als die in der deutschen Patentschrift 814 150 beschriebenen. Ferner ist z. B. das l,2-Diphenyl-4-(3'-oxobutyl)-3,5-dioxo-pyrazolidin nach Formel I annähernd 4mal weniger toxisch (Maus i. v.) als das entsprechende l,2-Diphenyl-4-n-butyl-3,5-dioxo-pyrazolidin gemäß 40 man dieser deutschen Patentschrift.The compounds according to formulas I and II show a much stronger uricosuric effect on humans, than those described in German Patent 814 150. Furthermore, z. B. 1,2-Diphenyl-4- (3'-oxobutyl) -3,5-dioxo-pyrazolidine according to formula I almost 4 times less toxic (mouse IV) than the corresponding 1,2-diphenyl-4-n-butyl-3,5-dioxo-pyrazolidine according to 40 man of this German patent specification.
Die oben definierten Ketale der allgemeinen Formel II und die ihnen zugrunde liegenden Oxoverbindungen der allgemeinen Formel I kann man herstellen, indem manThe above-defined ketals of the general formula II and the oxo compounds on which they are based General formula I can be prepared by
a) einen substituierten Malonsäurediester der allgemeinen Formela) a substituted malonic diester of the general formula
worin X leicht abspaltbare Kohlenwasserstoffreste bedeutet, und R1 und R2, die oben gegebene Bedeutung haben, in an sich bekannter Weise in Gegenwart eines alkalischen Kondensationsmittels auf Hydrazobenzol bzw. ein Hydrazobenzolderivat der allgemeinen Formelwhere X is easily split off hydrocarbon radicals, and R 1 and R 2 , which have the meanings given above, in a manner known per se in the presence of an alkaline condensing agent on hydrazobenzene or a hydrazobenzene derivative of the general formula
Z1-N- Ar1 Z 1 -N- Ar 1
Z2-N- Ar2 Z 2 -N- Ar 2
worin Z1 und Z2 Wasserstoff oder leicht abspaltbare Reste, insbesondere Säurereste, bedeuten und Ar1 und Ar2 die oben gegebene Bedeutung haben, einwirken läßt oder daßwhere Z 1 and Z 2 are hydrogen or easily split off radicals, in particular acid radicals, and Ar 1 and Ar 2 have the meaning given above, can act or that
b) ein substituiertes Malonsäurederivat der allgemeinen Formelb) a substituted malonic acid derivative of the general formula
,CO-Y, CO-Y
co—ο —χco — ο —χ
CH3-C-CH2-CH2-CHCH 3 -C-CH 2 -CH 2 -CH
IIIIII
R1 R 1
C—CHg-—C — CHg-—
—CH—CH
CO-CO-
O
RiO
Ri
O
R,O
R,
CO-0 —XCO-0 -X
worin Y Chlor, Brom oder einen Acyloxyrest bedeutet und R1 und R2 die oben angegebene Bedeutung haben, in an sich bekannter Weise, in Gegenwart eines säurebindenden Mittels auf Hydrazobenzol bzw. ein substituiertes Hy-wherein Y is chlorine, bromine or an acyloxy radical and R 1 and R 2 have the meaning given above, in a manner known per se, in the presence of an acid-binding agent on hydrazobenzene or a substituted hy-
«09 600/458«09 600/458
drazobenzol der allgemeinen Formel IV einwirken läßt oder daß mandrazobenzene of the general formula IV lets act or that one
c) ein substituiertes Malonsäure-ester-derivat der allgemeinen Formelc) a substituted malonic acid ester derivative of the general formula
CO- O — XCO-O-X
CH, — C-CH2 CH, - C-CH 2
-CH2-CH-CH 2 -CH
VIVI
CO-YCO-Y
worin R1, R2, X und Y die oben angegebene Bedeutung haben, in an sich bekannter Weise in Gegenwart eines säurebindenden Mittels auf Hydrazobenzol bzw. ein substituiertes Hydrazobenzol der allgemeinen Formel IV einwirken läßt, und das so erhaltene substituierte Malonsäure-ester-hydrazid der allgemeinen Formelwherein R 1 , R 2 , X and Y have the meaning given above, allowed to act in a manner known per se in the presence of an acid-binding agent on hydrazobenzene or a substituted hydrazobenzene of the general formula IV, and the substituted malonic acid ester hydrazide thus obtained the general formula
\-CH
\
VIIVII
H8C1 H 8 C 1
, CO — N — Ar1 , CO - N - Ar 1
CO — N — Ar,CO - N - Ar,
tralem Medium und, sofern die y-Oxogruppe ketalisiert ist, auch Raney-Nickel in alkalischem Medium.neutral medium and, provided that the γ-oxo group is ketalized is, also Raney nickel in an alkaline medium.
Die Reaktionsprodukte lassen sich in analoger Weise umwandeln oder in Salze überführen, wie dies vorstehend für die Produkte der Ringschlußverfahren angegeben ist.The reaction products can be converted or converted into salts in an analogous manner as described above for the products of the ring closure process is specified.
Das nachfolgende Beispiel soll die Herstellung der neuen Verbindungen näher erläutern. Teile bedeuten darin Gewichtsteile, diese verhalten sich zu Volumteilen wie g zu cm3.The following example is intended to explain the production of the new compounds in more detail. In it, parts mean parts by weight; these relate to parts by volume as g to cm 3 .
a) 1,2-Diphenyl-4-(3',3'-äthylendioxybutyl)-3,5-dioxo-pyrazolidin a) 1,2-Diphenyl-4- (3 ', 3'-ethylenedioxybutyl) -3,5-dioxo-pyrazolidine
274 Teile (3,3-Äthylendioxy-butyl)-malonsäure-diäthylester werden in 100 Volumteilen abs. Benzol gelöst und mit 57 Teilen Natriummethylat und 184 Teilen Hydrazobenzol versetzt. Es tritt Erwärmung ein. Die Reaktionsmasse wird 15 Stunden lang am Rückfluß gekocht. Nach 274 parts of (3,3-ethylenedioxy-butyl) malonic acid diethyl ester are abs in 100 parts by volume. Benzene dissolved and 57 parts of sodium methylate and 184 parts of hydrazobenzene are added. Warming occurs. The reaction mass is refluxed for 15 hours. To
ao dem Erkalten wird in Wasser gegossen, abgetrennt und der wäßrige Anteil 2mal mit Benzol gewaschen. Die Benzollösungen werden 3 mal mit 2-normaler Sodalösung gewaschen und die vereinigten wäßrigen Lösungen mit 2-normaler Salzsäure angesäuert. Das ausgefallene 1,2-Diphenyl-4-(3'-3'äthylendioxy-butyl)-3,5-dioxo-pyrazolidin kann aus Alkohol umkristallisiert werden. Schmp. 165 bis 167° C.After cooling, it is poured into water, separated off and the aqueous portion is washed twice with benzene. the Benzene solutions are washed 3 times with 2 normal sodium carbonate solution and the combined aqueous solutions with Acidified with 2 normal hydrochloric acid. The precipitated 1,2-diphenyl-4- (3'-3'äthylenedioxy-butyl) -3,5-dioxo-pyrazolidine can be recrystallized from alcohol. Mp. 165 to 167 ° C.
worin R1, R2, Ar1, Ar2 und X die oben angegebene Bedeutung haben, zur Schließung des Ringes erwärmt, nötigenfalls in Gegenwart eine alkalischen Kondensationsmittels, und hierauf gewünschtenfalls die gemäß irgendeiner der drei beschriebenen Verfahrensmodifikationen a), b) oder c) enthaltenen Ketalverbindungen der allgemeinen Formel II durch Hydrolyse oder durch Umketalisierung mit einer Oxoverbindung, z. B. in Gegenwart von wenig Chlorwasserstoff, in freie Oxoverbindungen der allgemeinen Formel I überführt oder gewünschtenfalls durch Umketalisierung mit einer Hydroxylverbindung die Reste R1 und R2 durch andere definitionsgemäße Reste R1 und R2 ersetzt und/oder gewünschtenfalls Verbindungen der allgemeinen Formeln I oder II in ihre Salze mit anorganischen oder organischen Basen überführt.wherein R 1 , R 2 , Ar 1 , Ar 2 and X have the meaning given above, heated to close the ring, if necessary in the presence of an alkaline condensing agent, and then, if desired, according to any of the three described process modifications a), b) or c ) contained ketal compounds of general formula II by hydrolysis or by transketalization with an oxo compound, eg. B. in the presence of a little hydrogen chloride, converted into free oxo compounds of the general formula I or, if desired, by transketalization with a hydroxyl compound, the radicals R 1 and R 2 are replaced by other defined radicals R 1 and R 2 and / or, if desired, compounds of the general formulas I or II converted into their salts with inorganic or organic bases.
Während man mittels aller vorstehend genannten Verfahren smodifikationen bei der ringschließenden Kondensation Pyrazolidinderivate erhält, welche das Kohlenstoffgerüst in 4-Stellung bereits enthalten, kann man die y-Oxo-butylgruppe bzw. ketalisierte y-Oxo-butylgruppen in bereits bestehenden Pyrazolidinderivate auch nachträglich einführen, indem man ein l,2-Diaryl-3,5-dioxopyrazolidin der allgemeinen FormelWhile all of the above-mentioned methods are used to make modifications to the ring-closing condensation Pyrazolidine derivatives which already contain the carbon structure in the 4-position can be obtained y-oxo-butyl group or ketalized y-oxo-butyl groups also subsequently introduce into existing pyrazolidine derivatives by adding a 1,2-diaryl-3,5-dioxopyrazolidine the general formula
b) l,2-Diphenyl-4-(3'-oxobutyl)-3,5-dioxo-pyrazolidin b) 1,2-diphenyl-4- (3'-oxobutyl) -3,5-dioxo-pyrazolidine
36,6 Teile l,2-Diphenyl-4-(3',3'-äthylendioxybutyl)-3,5-dioxo-pyrazolidin werden in 750 Volumteilen Aceton mit 0,35 Teilen p-Toluolsulfosäure 18 Stunden lang am Rückfluß erhitzt. Dann wird die Lösung filtriert, mit 1500 Teilen Wasser versetzt und 24 Stunden lang bei 5°C stehengelassen. Das ausgefallene l,2-Diphenyl-4-(3'-oxobutyl)-3,5-dioxo-pyrazolidin wird abgesaugt und mit 50 "/„igem Aceton gewaschen. Schmp. 115,5bisll6,5°Caus Alkohol-Wasser-Gemisch. Gelegentlich wird eine bei 127,5 bis 128,50C schmelzende Kristallform erhalten.36.6 parts of 1,2-diphenyl-4- (3 ', 3'-ethylenedioxybutyl) -3,5-dioxo-pyrazolidine are refluxed in 750 parts by volume of acetone with 0.35 parts of p-toluenesulfonic acid for 18 hours. The solution is then filtered, 1500 parts of water are added and the mixture is left to stand at 5 ° C. for 24 hours. The precipitated 1,2-diphenyl-4- (3'-oxobutyl) -3,5-dioxo-pyrazolidine is filtered off with suction and washed with 50% acetone . Occasionally is obtained melting at 127.5 to 128.5 0 C crystal form.
Claims (2)
O O / '\
OO
allgemeinen Formelc) a substituted one
general formula
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH1038049X | 1954-09-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE1038049B true DE1038049B (en) | 1958-09-04 |
Family
ID=4554094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DEG17950A Pending DE1038049B (en) | 1954-09-10 | 1955-09-09 | Process for the preparation of therapeutically valuable 4-substituted 1, 2-diaryl-3, 5-dioxo-pyrazolidines and their salts |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE1038049B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3123616A (en) * | 1960-05-27 | 1964-03-03 | C o nxe |
-
1955
- 1955-09-09 DE DEG17950A patent/DE1038049B/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3123616A (en) * | 1960-05-27 | 1964-03-03 | C o nxe |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2427272C3 (en) | 1- (2- (β-Naphthyloxy) ethyl) -3-methyl-pyrazolone- (5), method and use as an antithrombotic | |
DE1038049B (en) | Process for the preparation of therapeutically valuable 4-substituted 1, 2-diaryl-3, 5-dioxo-pyrazolidines and their salts | |
DE2356654A1 (en) | PROTOBERBERIN DERIVATIVES AND METHOD FOR PRODUCING THE SAME | |
DE2263026A1 (en) | AMIDE DERIVATIVES OF PYRIDINCARBONIC ACIDS | |
DE949232C (en) | Process for the production of therapeutically valuable basic substituted acetic acid esters | |
DE825416C (en) | Process for the preparation of tertiary amines | |
DE969245C (en) | Process for the production of new spasmolytically effective basic esters of ª ‡ -alkylated phenylacetic acids | |
DE887649C (en) | Process for the preparation of unsaturated amines suitable as antispasmodics | |
DE1468817C3 (en) | Process for the preparation of Bicycle- [2,2,2] -oct-2-en-1-carboxylic acids and their esters | |
DE1643797A1 (en) | New thionocarbamic acid esters and processes for their preparation | |
DE1470102A1 (en) | 2-Hydroxymethyl-5-nitroimidazoles and process for their preparation | |
DE568549C (en) | Process for the preparation of 2-alkoxy-5-nitropyridines | |
DE1157626B (en) | Process for the preparation of N-p-alkoxy-phenyl-N'-quinolylthioureas with tuberculostatic properties | |
DE96105C (en) | ||
DE2134289C3 (en) | Pyrazole derivatives | |
DE1620496C (en) | 1-pyridyl-3,4-dihydroisoquinolines and a process for their preparation | |
DE896651C (en) | Process for the preparation of thiocarbhydrazine compounds | |
DE633981C (en) | Process for the preparation of well-defined crystalline nitrates of phenylmercuric hydroxide | |
DE957036C (en) | Process for the production of new diammonium compounds that influence muscle tone | |
DE1795270C3 (en) | 1-hydroxy-2-pyridone | |
DE1924451C3 (en) | Process for the preparation of 2-methylamino-5-phenyl-3H-1,4-benzodiazepine-4-oxide derivatives | |
DE663543C (en) | Process for the production of Abkoemmlingen the pyrazine monocarboxylic acid | |
DE494508C (en) | Process for the preparation of a condensation product from m-cresol and acetone | |
DE949660C (en) | Process for the preparation of derivatives of 4-oxycoumarin | |
DE1064067B (en) | Process for the preparation of the therapeutically effective 1,2-diphenyl-3,5-dioxo-pyrazolidines substituted in the 4-position by a gamma- or delta-oxybutyl radical |